PT  - JOURNAL ARTICLE
AU  - Bjarke Frost Nielsen
AU  - Yimei Li
AU  - Kim Sneppen
AU  - Lone Simonsen
AU  - Cécile Viboud
AU  - Simon A. Levin
AU  - Bryan T. Grenfell
TI  - Immune Heterogeneity and Epistasis Explain Punctuated Evolution of SARS-CoV-2
AID  - 10.1101/2022.07.27.22278129
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.27.22278129
4099  - http://medrxiv.org/content/early/2022/07/29/2022.07.27.22278129.short
4100  - http://medrxiv.org/content/early/2022/07/29/2022.07.27.22278129.full
AB  - Identifying drivers of viral diversity is key to understanding the evolutionary as well as epidemiological dynamics of the COVID-19 pandemic. Using rich viral genomic data sets, we show that periods of steadily rising diversity have been punctuated by sudden, enormous increases followed by similarly abrupt collapses of diversity. We introduce a mechanistic model of saltational evolution with epistasis and demonstrate that these features parsimoniously account for the observed temporal dynamics of inter-genomic diversity. Our results provide support for recent proposals that saltational evolution may be a signature feature of SARS-CoV-2, allowing the pathogen to more readily evolve highly transmissible variants. These findings lend theoretical support to a heightened awareness of biological contexts where increased diversification may occur. They also underline the power of pathogen genomics and other surveillance streams in clarifying the phylodynamics of emerging and endemic infections. In public health terms, our results further underline the importance of equitable distribution of up-to-date vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBFN and LS received funding from the Carlsberg Foundation under its Semper Ardens programme (grant #CF20-0046, BFN and LS). BTG received funding from the Flu Lab. SAL acknowledges the support of the the C3.ai Digital Transformation Institute and Microsoft Corporation, Gift from Google and the National Science Foundation (CNS-2027908, CCF1917819).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code produced in the present study are available upon reasonable request to the authors.